-
Barber D L, Wherry E J, Masopust D, Zhu B, Allison J P, Sharpe A H, Freeman G J, Ahmed R, 2006: Restoring function in exhausted CD8 T cells during chronic viral infection[J]. Nature, 439, 682-687. doi: 10.1038/nature04444
-
Blum H E, Gerok W, Vyas G N, 1989: The molecular biology of hepatitis B virus[J]. Trends Genet: TIG, 5, 154-158. doi: 10.1016/0168-9525(89)90057-7
-
Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C, 1998: Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B[J]. J Clin Invest, 102, 968-975. doi: 10.1172/JCI3731
-
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C, 2007: Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection[J]. J Virol, 81, 4215-4225. doi: 10.1128/JVI.02844-06
-
Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C, 2003: Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B[J]. J Hepatol, 39, 595-605. doi: 10.1016/S0168-8278(03)00292-7
-
Chisari F V, Isogawa M, Wieland S F, 2010: Pathogenesis of hepatitis B virus infection[J]. Pathol Biol, 58, 258-266. doi: 10.1016/j.patbio.2009.11.001
-
Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, Michel M L, 1999: Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens[J]. J Infect Dis, 180, 15-26. doi: 10.1086/314828
-
Dahmen A, Herzog-Hauff S, Bocher W O, Galle P R, Lohr H F, 2002: Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B[J]. J Med Virol, 66, 452-460. doi: 10.1002/jmv.2165
-
Dandri M, Locarnini S, 2012: New insight in the pathobiology of hepatitis B virus infection[J]. Gut, 61, i6-17. doi: 10.1136/gutjnl-2012-302056
-
Day C L, Kaufmann D E, Kiepiela P, Brown J A, Moodley E S, Reddy S, Mackey E W, Miller J D, Leslie A J, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry E J, Coovadia H M, Goulder P J, Klenerman P, Ahmed R, Freeman G J, Walker B D, 2006: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression[J]. Nature, 443, 350-354. doi: 10.1038/nature05115
-
Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A, Haspolat K, 2003: Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection[J]. J Gastroen Hepatol, 18, 218-222. doi: 10.1046/j.1440-1746.2003.02950.x
-
Fiedler M, Kosinska A, Schumann A, Brovko O, Walker A, Lu M, Johrden L, Mayer A, Wildner O, Roggendorf M, 2013: Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus[J]. J Virol, 87, 7708-7716. doi: 10.1128/JVI.00645-13
-
Finnefrock A C, Tang A, Li F, Freed D C, Feng M, Cox K S, Sykes K J, Guare J P, Miller M D, Olsen D B, Hazuda D J, Shiver J W, Casimiro D R, Fu T M, 2009: PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination[J]. J Immunol, 182, 980-987. doi: 10.4049/jimmunol.182.2.980
-
Freeman G J, Wherry E J, Ahmed R, Sharpe A H, 2006: Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade[J]. J Exp Med, 203, 2223-2227. doi: 10.1084/jem.20061800
-
Ganem D, Prince A M, 2004: Hepatitis B virus infection--natural history and clinical consequences[J]. New Engl J Med, 350, 1118-1129. doi: 10.1056/NEJMra031087
-
Ha S J, Mueller S N, Wherry E J, Barber D L, Aubert R D, Sharpe A H, Freeman G J, Ahmed R, 2008: Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection[J]. J Exp Med, 205, 543-555. doi: 10.1084/jem.20071949
-
Hervas-Stubbs S, Lasarte J J, Sarobe P, Vivas I, Condreay L, Cullen J M, Prieto J, Borras-Cuesta F, 2001: T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine[J]. J Hepatol, 35, 105-111. doi: 10.1016/S0168-8278(01)00063-0
-
Horiike N, Fazle Akbar S M, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M, 2005: In vivo immunization by vaccine therapy following virus suppression by lamivudine:a novel approach for treating patients with chronic hepatitis B[J]. J Clin Virol:the official publication of the Pan American Society for Clinical Virology, 32, 156-161. doi: 10.1016/j.jcv.2004.07.004
-
Jung M C, Spengler U, Schraut W, Hoffmann R, Zachoval R, Eisenburg J, Eichenlaub D, Riethmuller G, Paumgartner G, Ziegler-Heitbrock H W, 1991: Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B[J]. J Hepatol, 13, 310-317.
-
Jung M C, Gruner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, Schirren C A, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S, Pape G R, 2002: Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies:induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers[J]. Vaccine, 20, 3598-3612. doi: 10.1016/S0264-410X(02)00309-2
-
Kosinska A D, Johrden L, Zhang E, Fiedler M, Mayer A, Wildner O, Lu M, Roggendorf M, 2012: DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model[J]. J Virol, 86, 9297-9310. doi: 10.1128/JVI.00506-12
-
Kosinska A D, Zhang E, Johrden L, Liu J, Seiz P L, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, Roggendorf M, 2013: Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model[J]. PLoS Pathog, 9, e1003391-. doi: 10.1371/journal.ppat.1003391
-
Li F J, Zhang Y, Jin G X, Yao L, Wu D Q, 2013: Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients[J]. Immunol Lett, 150, 116-122. doi: 10.1016/j.imlet.2012.12.004
-
Liang T J, 2009: Hepatitis B:the virus and disease[J]. Hepatology, 49, S13-21. doi: 10.1002/hep.22881
-
Locarnini S, Mason W S, 2006: Cellular and virological mechanisms of HBV drug resistance[J]. J Hepatol, 44, 422-431. doi: 10.1016/j.jhep.2005.11.036
-
Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, Chi H, Dirsch O, Kemper T, He L, Glebe D, Gerlich W H, Wen Y, Roggendorf M, 2008: Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model[J]. J Virol, 82, 2598-2603. doi: 10.1128/JVI.01613-07
-
Maier H, Isogawa M, Freeman G J, Chisari F V, 2007: PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver[J]. J Immunol, 178, 2714-2720. doi: 10.4049/jimmunol.178.5.2714
-
Maini M K, Boni C, Lee C K, Larrubia J R, Reignat S, Ogg G S, King A S, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov N V, Ferrari C, Bertoletti A, 2000: The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection[J]. J Exp Med, 191, 1269-1280. doi: 10.1084/jem.191.8.1269
-
Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel M L, 2006: Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers[J]. Vaccine, 24, 4482-4489. doi: 10.1016/j.vaccine.2005.08.013
-
Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel M L, 2004: Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers[J]. Hepatology, 40, 874-882.
-
Menne S, Roneker C A, Tennant B C, Korba B E, Gerin J L, Cote P J, 2002: Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection[J]. Intervirology, 45, 237-250. doi: 10.1159/000067914
-
Menne S, Roneker C A, Korba B E, Gerin J L, Tennant B C, Cote P J, 2002: Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection[J]. J Virol, 76, 5305-5314. doi: 10.1128/JVI.76.11.5305-5314.2002
-
Paoletti E, 1996: Applications of pox virus vectors to vaccination:an update[J]. P Natl Acad Sci USA, 93, 11349-11353. doi: 10.1073/pnas.93.21.11349
-
Penna A, Chisari F V, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C, 1991: Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen[J]. J Exp Med, 174, 1565-1570. doi: 10.1084/jem.174.6.1565
-
Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C, 2007: Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection[J]. Hepatology, 45, 588-601. doi: 10.1002/hep.21541
-
Perkus M E, Piccini A, Lipinskas B R, Paoletti E, 1985: Recombinant vaccinia virus: immunization against multiple pathogens[J]. Science, 229, 981-984. doi: 10.1126/science.2992092
-
Petrovas C, Casazza J P, Brenchley J M, Price D A, Gostick E, Adams W C, Precopio M L, Schacker T, Roederer M, Douek D C, Koup R A, 2006: PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection[J]. J Exp Med, 203, 2281-2292. doi: 10.1084/jem.20061496
-
Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky J M, Zeuzem S, Schalm S W, von Wagner M, Germanidis G, Lurie Y, Esteban J I, Haagmans B L, Hezode C, Lagging M, Negro F, Homburger Y, Neumann A U, Ferrari C, Missale G, 2007: HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)[J]. Gastroenterology, 133, 1132-1143. doi: 10.1053/j.gastro.2007.06.059
-
Pol S, Driss F, Michel M L, Nalpas B, Berthelot P, Brechot C, 1994: Specific vaccine therapy in chronic hepatitis B infection[J]. Lancet, 344, 342-.
-
Pol S, Nalpas B, Driss F, Michel M L, Tiollais P, Denis J, Brecho C, 2001: Efficacy and limitations of a specific immunotherapy in chronic hepatitis B[J]. J Hepatol, 34, 917-921. doi: 10.1016/S0168-8278(01)00028-9
-
Rehermann B, Nascimbeni M, 2005: Immunology of hepatitis B virus and hepatitis C virus infection[J]. Nat Rev Immunol, 5, 215-229. doi: 10.1038/nri1573
-
Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, Furutani M, Yamasaki T, Korenaga K, Yamashita S, Konishi T, Okita K, 2003: Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection[J]. J Med Virol, 71, 376-384. doi: 10.1002/jmv.10509
-
Robinson H L, 2002: New hope for an AIDS vaccine[J]. Nature reviews. Immunology, 2, 239-250. doi: 10.1038/nri776
-
Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, Rowe M, Alper R, Klein A, Hemed N, Segol O, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y, 2003: Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins[J]. Am J Gastroenterol, 98, 2505-2515. doi: 10.1111/j.1572-0241.2003.07700.x
-
Sallberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K, Anderson C G, O'Dea J, Alfonso J, Eason R, Murthy K K, Jolly D J, Chang S M, Mento S J, Milich D, Lee W T, 1998: Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen[J]. Hum Gene Ther, 9, 1719-1729. doi: 10.1089/hum.1998.9.12-1719
-
Schurich A, Khanna P, Lopes A R, Han K J, Peppa D, Micco L, Nebbia G, Kennedy P T, Geretti A M, Dusheiko G, Maini M K, 2011: Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection[J]. Hepatology, 53, 1494-1503. doi: 10.1002/hep.24249
-
Tatsis N, Ertl H C, 2004: Adenoviruses as vaccine vectors[J]. Mol Ther, 10, 616-629. doi: 10.1016/j.ymthe.2004.07.013
-
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann K A, Purcell R H, Chisari F V, 2003: CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection[J]. J Virol, 77, 68-76. doi: 10.1128/JVI.77.1.68-76.2003
-
Trautmann L, Janbazian L, Chomont N, Said E A, Gimmig S, Bessette B, Boulassel M R, Delwart E, Sepulveda H, Balderas R S, Routy J P, Haddad E K, Sekaly R P, 2006: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction[J]. Nat Med, 12, 1198-1202. doi: 10.1038/nm1482
-
Vandepapeliere P, Lau G K, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican M I, Win K M, Trepo C, Cooksley G, Wettendorff M, Ferrari C, 2007: Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy:a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine[J]. Vaccine, 25, 8585-8597. doi: 10.1016/j.vaccine.2007.09.072
-
Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford T H, Chennareddi L, Silvestri G, Freeman G J, Ahmed R, Amara R R, 2009: Enhancing SIV-specific immunity in vivo by PD-1 blockade[J]. Nature, 458, 206-210. doi: 10.1038/nature07662
-
Wang X Y, Zhang X X, Yao X, Jiang J H, Xie Y H, Yuan Z H, Wen Y M, 2010: Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine[J]. Vaccine, 28, 8169-8174. doi: 10.1016/j.vaccine.2010.09.093
-
Webster G J, Reignat S, Brown D, Ogg G S, Jones L, Seneviratne S L, Williams R, Dusheiko G, Bertoletti A, 2004: Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy[J]. J Virol, 78, 5707-5719. doi: 10.1128/JVI.78.11.5707-5719.2004
-
Wen Y M, Wu X H, Hu D C, Zhang Q P, Guo S Q, 1995: Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy[J]. Lancet, 345, 1575-1576.
-
Wu C, Shi H, Wang Y, Lu M, Xu Y, Chen X, 2012: A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy[J]. Virol Sin, 27, 369-372.
-
Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y, Chen Z, 2012: Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B[J]. Eur J Immunol, 42, 1180-1191. doi: 10.1002/eji.201141852
-
Xu D Z, Zhao K, Guo L M, Li L J, Xie Q, Ren H, Zhang J M, Xu M, Wang H F, Huang W X, Bai X F, Niu J Q, Liu P, Chen X Y, Shen X L, Yuan Z H, Wang X Y, Wen Y M, 2008: A randomized controlled phase Ⅱb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients[J]. PloS One, 3, e2565-. doi: 10.1371/journal.pone.0002565
-
Xu D Z, Wang X Y, Shen X L, Gong G Z, Ren H, Guo L M, Sun A M, Xu M, Li L J, Guo X H, Zhen Z, Wang H F, Gong H Y, Xu C, Jiang N, Pan C, Gong Z J, Zhang J M, Shang J, Xu J, Xie Q, Wu T F, Huang W X, Li Y G, Yuan Z H, Wang B, Zhao K, Wen Y M, 2013: Results of a phase Ⅲ clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings[J]. J Hepatol, 59, 450-456. doi: 10.1016/j.jhep.2013.05.003
-
Yalcin K, Acar M, Degertekin H, 2003: Specific hepatitis B vaccine therapy in inactive HBsAg carriers:a randomized controlled trial[J]. Infection, 31, 221-225.
-
Yang P L, Althage A, Chung J, Maier H, Wieland S, Isogawa M, Chisari F V, 2010: Immune effectors required for hepatitis B virus clearance[J]. Proc Natl Acad Sci U S A, 107, 798-802. doi: 10.1073/pnas.0913498107
-
Yao X, Zheng B, Zhou J, Xu D Z, Zhao K, Sun S H, Yuan Z H, Wen Y M, 2007: Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients[J]. Vaccine, 25, 1771-1779. doi: 10.1016/j.vaccine.2006.11.019
-
Zoulim F, and Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 137: 1593-1608 e1591-1592.